The proteasome inhibitior bortezomib depletes plasma cells and ameliorates clinical manifestations of refractory systemic lupus erythematosus

OBJECTIVES: To investigate whether bortezomib, a proteasome inhibitor approved for treatment of multiple myeloma, induces clinically relevant plasma cell (PC) depletion in patients with active, refractory systemic lupus erythematosus (SLE). METHODS: Twelve patients received a median of two (range 1–...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ann Rheum Dis
Main Authors: Alexander, Tobias, Sarfert, Ramona, Klotsche, Jens, Kühl, Anja A, Rubbert-Roth, Andrea, Lorenz, Hannes-Martin, Rech, Jürgen, Hoyer, Bimba F, Cheng, Qingyu, Waka, Aderajew, Taddeo, Adriano, Wiesener, Michael, Schett, Georg, Burmester, Gerd-Rüdiger, Radbruch, Andreas, Hiepe, Falk, Voll, Reinhard E
Formato: Artigo
Idioma:Inglês
Publicado em: BMJ Publishing Group 2015
Assuntos:
Basic and Translational Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4484251/
https://ncbi.nlm.nih.gov/pubmed/25710470
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/annrheumdis-2014-206016
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados